CAMP4 Therapeutics Corporation (CAMP)
Automate Your Wheel Strategy on CAMP
With Tiblio's Option Bot, you can configure your own wheel strategy including CAMP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CAMP
- Rev/Share 0.1492
- Book/Share 1.9835
- PB 1.9712
- Debt/Equity 0.1782
- CurrentRatio 5.6014
- ROIC -1.0675
- MktCap 78829795.0
- FreeCF/Share -2.2893
- PFCF -1.708
- PE -1.5222
- Debt/Assets 0.1389
- DivYield 0
- ROE -1.312
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CAMP | Cantor Fitzgerald | -- | Overweight | -- | $7 | Oct. 2, 2025 |
| Downgrade | CAMP | JP Morgan | Overweight | Neutral | -- | -- | Sept. 16, 2025 |
| Initiation | CAMP | Wedbush | -- | Outperform | -- | $8 | May 27, 2025 |
News
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
CAMP4 Therapeutics Corporation (CAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes
Read More
CalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025
Published: March 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108 Leading Fleet Management Innovator to Engage with Industry Experts at Booth 108
Read More
About CAMP4 Therapeutics Corporation (CAMP)
- IPO Date 2024-10-11
- Website https://www.camp4tx.com
- Industry Biotechnology
- CEO Joshua Mandel-Brehm
- Employees 55